TABLE 2.
Baseline Characteristics of Patients With Unresected Disease by Recurrence Statusa
| With recurrence (n = 791) | Without recurrence (n = 426) | P value | |
|---|---|---|---|
| Demographic characteristics | |||
| Age at diagnosis, years | 0.007 | ||
| Mean±SD | 73.3 ±5.9 | 74.4 ±7.2 | |
| Median (IQR) | 71.8 (68.8-76.4) | 72.4 (68.7-78.2) | |
| Age at index, years | 0.077 | ||
| Mean±SD | 74.6 ±5.9 | 75.3 ±7.1 | |
| Median (IQR) | 73.4 (70.1-77.9) | 73.6 (69.5-79.1) | |
| Male, n (%) | 553 (69.9) | 269 (63.1) | 0.016 |
| Race and ethnicity, n (%) | 0.109 | ||
| White | 669 (84.6) | 345 (81.0) | |
| Others | 122 (15.4) | 81 (19.0) | |
| Residential area at diagnosis, n (%) | 0.301 | ||
| Metropolitan areas | 654 (82.7) | 342 (80.3) | |
| Nonmetropolitan areas | 137 (17.3) | 84 (19.7) | |
| Region, n (%) | 0.010 | ||
| West | 349 (44.1) | 158 (37.1) | |
| South | 206 (26.0) | 142 (33.3) | |
| Northeast | 134 (16.9) | 83 (19.5) | |
| Midwest | 102 (12.9) | 43 (10.1) | |
| Year of initial diagnosis, n (%) | 0.206 | ||
| 2007-2010 | 166 (21.0) | 82 (19.2) | |
| 2011-2014 | 310 (39.2) | 140 (32.9) | |
| 2015-2019 | 315 (39.8) | 204 (47.9) | |
| Primary payer at initial diagnosis, n (%) | 0.539 | ||
| Medicare | 603 (76.2) | 318 (74.6) | |
| Others | 188 (23.8) | 108 (25.4) | |
| Clinical characteristics | |||
| Disease stage group, n (%) | 0.105 | ||
| Stage III | 264 (33.4) | 172 (40.4) | |
| Stage IVa | 455 (57.5) | 213 (50.0) | |
| Stage IVb | 51 (6.4) | 31 (7.3) | |
| Stage IV unspecified | >10 (>1.3) | <11 (<2.6) | |
| Missing stage | <11 (<1.4) | <11 (<2.6) | |
| Tumor site at diagnosis, n (%) | 0.694 | ||
| Oropharynx | 318 (40.2) | 163 (38.3) | |
| Larynx | 227 (28.7) | 127 (29.8) | |
| Oral cavity | 192 (24.3) | 112 (26.3) | |
| Hypopharynx | 54 (6.8) | 24 (5.6) | |
| Tumor size at diagnosis, cm | |||
| Mean±SD | 3.7 ±4.3 | 3.6 ±1.8 | |
| Median (IQR) | 3.3 (2.5-4.5) | 3.4 (2.4-4.5) | |
| Missing observations | 172 | 93 | |
| Comorbidity profile | |||
| CCI scoreb | 0.755 | ||
| Mean±SD | 1.6 ±1.6 | 1.6 ±1.8 | |
| Median (IQR) | 1.0 (0.0-3.0) | 1.0 (0.0-3.0) | |
| Primary treatment pattern, n (%) | 0.062 | ||
| Radiation therapy only | >221 (>27.9) | >132 (>31.0) | |
| Systemic therapy only | <11 (<1.4) | <11 (<1.4) | |
| Systemic therapy+radiation therapy | 559 (70.7) | 283 (66.4) | |
| Annualized all-cause health care costs per patient, mean±SD [median], 2023 USD | 51,169 53,625 [38,166] | 61,890 ±60,620 [43,321] | <0.001 |
| Annualized HNSCC-related health care costs per patient, mean±SD [median], 2023 USD | 27,989 ±39,290 [12,299] | 33,891 ±43,440 [17,735] | <0.001 |
P values less than 0.05 were considered statistically significant.
Categories with n less than 11 were suppressed.
The conditions included in the CCI were identified using International Classification of Diseases, Ninth and Tenth Revisions diagnosis codes reported by Quan et al (2005), excluding codes for cancer (Quan H, Sundararajan V, Halfon P, et al, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-9. doi:10.1097/01.mlr.0000182534.19832.83). The CCI weights were based on Quan et al (2011) (Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-82. doi:10.1093/aje/kwq433).
CCI = Charlson comorbidity index; HNSCC = head and neck squamous cell carcinoma; USD = United States dollars.